Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of concurrent antiplatelet/NSAID use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial

View Full Paper
Ask AI
Bookmark
Share

Authors

DHDanny HillPWPhilip S. WellsMCMarc Carrier

Discussion

Loading...

Member takes

Overview

Analysis demonstrates increased major bleeding risk in cancer patients using antiplatelet or NSAIDs during apixaban thromboprophylaxis, indicating a need for safety reassessment.

Key Points

  • Evaluate the effects of concurrent antiplatelet/NSAID use on apixaban thromboprophylaxis in cancer patients.
  • Post-hoc analysis of the AVERT trial data
  • Randomized, placebo-controlled, double-blind design
  • Patients included had Khorana scores ≥2 and were initiating chemotherapy
  • Analyzed primary outcome of clinically relevant bleeding and secondary outcomes including VTE and death
  • Calculated hazard ratios for outcomes among patients with and without concurrent antiplatelet/NSAID use
  • 557 patients analyzed, with 182 using concurrent antiplatelets/NSAIDs
  • Increased risk of clinically relevant bleeding (HR 1.78) and CRNMB (HR 1.98) in apixaban group with concurrent use
  • No significant difference in major bleeding risk between groups
  • Among antiplatelet users, higher risk of clinically relevant bleeding (HR 2.0) and CRNMB (HR 2.59)
  • In the placebo group, no increased bleeding risk associated with concurrent use

Cite This Study

Hill et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d31bhttps://doi.org/10.1182/blood-2025-741
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism2025
  2. 2Apixaban to Prevent Venous Thromboembolism in Patients with Cancer2018 · 858 citations
  3. 3Evaluation of the efficacy and safety of apixaban and rivaroxaban in cancer patients receiving concomitant active anti-neoplastic therapy at an outpatient cancer setting2020 · 1 citations
  4. 4Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism2023 · 6 citations
  5. 5Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study2025 · 6 citations